Martin Huber

2021 - Xilio Therapeutics

In 2021, Martin Huber earned a total compensation of $3.5M as President of R&D and Chief Medical Officer at Xilio Therapeutics, a 259% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$269,325
Option Awards$2,720,568
Salary$458,859
Other$11,272
Total$3,460,024

Huber received $2.7M in option awards, accounting for 79% of the total pay in 2021.

Huber also received $269.3K in non-equity incentive plan, $458.9K in salary and $11.3K in other compensation.

Rankings

In 2021, Martin Huber's compensation ranked 3,872nd out of 12,415 executives tracked by ExecPay. In other words, Huber earned more than 68.8% of executives.

ClassificationRankingPercentile
All
3,872
out of 12,415
69th
Division
Manufacturing
1,586
out of 5,505
71st
Major group
Chemicals And Allied Products
649
out of 2,375
73rd
Industry group
Drugs
577
out of 2,096
73rd
Industry
Pharmaceutical Preparations
404
out of 1,546
74th
Source: SEC filing on April 26, 2022.

Huber's colleagues

We found two more compensation records of executives who worked with Martin Huber at Xilio Therapeutics in 2021.

2021

René Russo

Xilio Therapeutics

Chief Executive Officer

2021

Salvatore Giovine

Xilio Therapeutics

Chief Financial Officer

News

In-depth

You may also like